Specialists from the Petrov National Medical Research Center for Oncology have won the national award “Vocation” for the development of a vaccine based on dendritic cells.
According to the researchers, this drug activates the immune system, allowing it to recognize tumors and initiate the body's defense mechanisms. Plans for its introduction into clinical practice are scheduled for 2026 for the treatment of sarcoma and melanoma.
In the coming years, we expect the results of clinical trials of different types of oncovaccines. With a high probability, this will lead to a significant improvement in oncology treatment outcomes,” Ivanov added.
Ivanov also noted that mRNA vaccines have the advantage of rapid adaptation to tumor specificity. Their production requires only RNA synthesis, which makes the process of their creation easier and cheaper.
Earlier we wrote about the fact that in Russia are testing a new rapid analysis that detects pancreatic cancer in 45 minutes. Russia has developed a vaccine against pertussis, tetanus and diphtheria.